SDZNY
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | 1.25 | $5.8B | $616M |
| 2025 Q2 | 0.87 | $5.3B | $320M |
| 2024 Q4 | -0.35 | $5.3B | $188M |
| 2024 Q2 | 0.35 | $5.1B | $64M |
| 2023 Q4 | -0.36 | $5.0B | $67M |
| 2023 Q2 | 0.55 | $4.9B | -$70M |
| 2022 Q4 | 0.00 | $4.6B | $728M |
| 2022 Q2 | 0.00 | $4.7B | $216M |